Baxter Ventures

NovaXS is developing the next generation of smart needle-free drug delivery platform that improves the medication adherence and optimizes the treatment outcomes.

Medically Home is a tech-enabled clinical enterprise that provides all the necessary capabilities to safely-shift medical care from hospitals to patients’ homes. Its platform offers a virtual hospital program that connects patients with caregivers and supports the monitoring of, and communication with patients with high acuity illness that help patients and their families to access a medical command center that provides centralized, on-demand acute medical care management from the comfort of their homes. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Walela is a medical device company that develops sensor technology to improve fetal and maternal outcomes. It measures fetal heart rate and blood pH using its specialized medical technology. The company was founded by James Balman in 2021 and is headquartered in Chicago, Illinois.

Hospital IQ is the leading predictive analytics platform applying proven operations research to improve hospital operational efficiency and patient quality through smarter data-driven decision making. The company works with a number of leading institutions including Brigham and Women’s Hospital to systematically optimize capacity, schedules, and staffing. Hospital IQ’s automated reporting, modeling, and prediction tools are used to improve utilization and throughput across a hospital or hospital network. Hospital IQ was founded by a veteran team of operations management and software engineers, in consultation with leading industry experts, driven by a mission to apply operations research principles to improve hospital efficiency.

Alvotech is a biopharmaceutical company that specializes in the development and manufacture of biosimilar medicines aimed at treating severe and chronic conditions. Founded in 2013 and headquartered in Reykjavík, Iceland, with additional facilities in Germany and Switzerland, Alvotech focuses on creating biosimilar versions of leading monoclonal antibodies. The company has six key biosimilar molecules in its development pipeline and has invested over $500 million in this endeavor. Alvotech aims to enhance patient access to effective treatments and improve the overall quality of life for individuals facing various health challenges. In pursuit of its goals, Alvotech has established strategic partnerships with prominent global pharmaceutical companies to facilitate the commercialization of its products.

MedaSense Biometrics Ltd. specializes in developing pain monitoring medical devices aimed at optimizing and personalizing pain management. The company's flagship product, the PMD-200, utilizes a proprietary non-invasive sensor and artificial intelligence to objectively measure patients' physiological responses to pain through its NOL® index. This device is particularly valuable in operating rooms and critical care settings where patients may be unable to communicate, addressing a significant market for pain management. MedaSense also provides the NOL-edge Hub, a collaborative platform intended to advance pain research and product development. Founded in 2008, the company operates from Ramat Gan, Israel, with an additional office in Longmont, Colorado. The PMD-200 is distributed in Europe through a partnership with Medtronic and has been cleared for marketing in several regions, including Canada, Latin America, and Australia. Clinical studies indicate that the device enhances patient safety and outcomes by supporting opioid-sparing strategies.

Seprafilm is a mechanical bioresorbable adhesion barrier that is applied to adhesiogenic tissues before surgical closure. It is indicated for the reduction in the incidence, extent, and severity of postoperative adhesions in patients undergoing abdominal or pelvic laparotomy.

Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.

Prescient Surgical, Inc. engages in the development of medical devices for the prevention of surgical site infection. The company offers Cleancision that prevents dangerous surgical wound infections. It provides products primarily for patients undergoing high-risk abdominal gastrointestinal surgery. The company was incorporated in 2012 and is based in Mountain View, California.

Outset Medical is a medical tech company that manufactures medical equipment. They provide reimagining dialysis for patients and health care providers. Their system comes equipped with wireless data, sensor-based automation, and an animated touchscreen to make the systems.

VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions.

BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India.

Claris Injectables Limited, a wholly-owned subsidiary of Claris Lifesciences Limited - collectively ‘Claris’, is a sterile injectables pharmaceutical company with its market presence across the world. Claris manufactures and/or markets products across multiple delivery systems, markets, and therapeutic segments, including anesthesia & analgesics, blood products, anti-infectives, critical care, and nephrology. A significant majority of these products are generic drugs, capable of being directly injected into the human body, predominantly used in the treatment of critical illnesses. Our customer base primarily includes government and semi-government institutions, group corporate hospitals, standalone prominent hospitals, and nursing homes. With emphasis on quality, technology, and innovation, we offer a range of niche technology-driven injectables products across delivery systems, such as bags (PVC & NPVC), vials, ampoules, glass bottles, etc. We have three manufacturing facilities at a campus located in Ahmedabad, India. Our sterile injectables facilities have been approved by regulatory authorities, including US FDA, MHRA (UK), TGA (Australia), MCC (South Africa), ANVISA (Brasil), INVIMA (Colombia), and GCC FDCA. Our manufacturing capabilities have enabled us earn several awards from prestigious institutions like IDMA (Indian Drug Manufacturers' Association) and Frost & Sullivan IMEA (India Manufacturing Excellence Award). Our capabilities and experience span across several business verticals in the specialty injectables industry. We have a trained workforce extending over all the business functions, such as product development, regulatory affairs for obtaining product registrations, manufacturing, and sales & marketing.

Bluesight solves supply chain inefficiencies and reduces risk by providing actionable analytics for every step of the medication lifecycle. Through the company's suite of Medication Intelligence solutions, Bluesight brings simplicity, visibility, and predictability to the complex of medication management.

MedaSense Biometrics Ltd. specializes in developing pain monitoring medical devices aimed at optimizing and personalizing pain management. The company's flagship product, the PMD-200, utilizes a proprietary non-invasive sensor and artificial intelligence to objectively measure patients' physiological responses to pain through its NOL® index. This device is particularly valuable in operating rooms and critical care settings where patients may be unable to communicate, addressing a significant market for pain management. MedaSense also provides the NOL-edge Hub, a collaborative platform intended to advance pain research and product development. Founded in 2008, the company operates from Ramat Gan, Israel, with an additional office in Longmont, Colorado. The PMD-200 is distributed in Europe through a partnership with Medtronic and has been cleared for marketing in several regions, including Canada, Latin America, and Australia. Clinical studies indicate that the device enhances patient safety and outcomes by supporting opioid-sparing strategies.

Opsonix is developing and commercializing a pathogen-extracting therapy that uses its proprietary pathogen-capture proteins to remove infectious microbes and the toxins they release from circulating blood, offering a new broad-spectrum approach to transform the treatment of blood-borne infectious diseases, including sepsis.

TVA Medical, Inc. (TVA) is a medical device company developing innovative, minimally invasive therapies for treatment of End-Stage Renal Disease (ESRD). The company is funded by Santé Ventures.

SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

AesRx (ǽs-r-ex) is a biopharmaceutical company dedicated to the development of two novel drugs, each of which targets an orphan disease. AesRx's lead program, Aes-103, is a potential breakthrough in the treatment of sickle cell disease. Sickle cell disease is a recessive disorder of the hemoglobin which can cause red blood cells to deform into rigid sickle shapes that block capillaries and other small blood vessels. This blockage can lead to a wide range of serious, sometimes life-threatening, conditions including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage to tissues and organs.

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.

Chatham Therapeutics LLC operates in the biotechnology sector. The company was formerly known as VECTORRX INC. The company was incorporated in 2010 and is based in Chapel Hill, North Carolina.

Xenetic is a leading UK-based biopharmaceutical company providing leading-edge expertise in the development of a whole new generation of drugs, cancer therapies, and vaccines. Xenetic Biosciences is formerly known as Lipoxen. Working with some of the largest pharmaceutical organizations in the world, Xenetic provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

The URINFO 2000 fluid monitoring system is the only feasible solution for the accurate, real-time, and continuous monitoring of urine output. The product is based on FlowSense’s patented optical flow sensing technology. URINFO2000 has been used in the critical care setting to optimize fluid and electrolyte balance, treat acute kidney injury, and prevent renal failure.

Gambro is a global medical technology company and a leader in developing, manufacturing and supplying products and therapies for Kidney and Liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for Chronic and Acute patients. Kidney (renal) dialysis was the world’s first extracorporeal therapy (i.e. a therapy that treats organ failure outside the body). Dialysis saves the lives of a growing number of patients every year, and innovation in the field is essential. The only current alternative to renal dialysis - kidney transplantation - is not an available option for most patients, due to a shortage of donor organs. Dialysis technology is now being developed for new applications such as liver dialysis and an emerging field of other extracorporeal therapies, to remove different fluids and toxins from chronically and acutely ill patients. For decades, Gambro has been first to market with many groundbreaking innovations. By designing and delivering solutions to dialysis clinics and intensive care units, Gambro offers not just improved treatment quality, but also improved efficiency. Gambro was founded in 1964 and has today 8 000 employees, 13 production facilities in 9 countries, and sales in more than 90 countries.

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Zytoprotec is an Austrian biotechnology company, founded in 2007 to apply ground-breaking findings in the area of cytoprotection to the development of new treatment options for major disease areas. The Company was founded by a team of professionals that combine extensive experience in business administration, clinical research, pharmaceutical product development, as well as company and patent law.

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.

Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.

Gliknik Inc. is a biopharmaceutical company based in Baltimore, Maryland, focused on developing therapies for cancer and immune disorders. Founded in 2007, the company offers several innovative treatments, including GL-0817, aimed at preventing the recurrence of squamous cell cancer of the oral cavity, and GL-2045, which targets a range of autoimmune diseases such as immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and Myasthenia gravis. Additionally, Gliknik is advancing GB-4542, an anti-CD20 monoclonal antibody therapy. The company's Immunomodulator Platform includes off-the-shelf peptide drugs to enhance immune responses, while the Stradomer Platform mimics the efficacy of human intravenous immunoglobulin, and the Stradobody Platform produces compounds akin to monoclonal antibodies for tumor cell destruction. Through these efforts, Gliknik aims to provide impactful therapies that alleviate suffering for patients with serious health conditions.

Synovis Surgical Innovations is a medical devices company that offers implantable biomaterial devices.

Baxa Corporation, a privately held global company based in Englewood, Colo.

Prism Pharmaceuticals, Inc., an acute care pharmaceutical company, engages in developing and commercializing cardiovascular injectable products in the United States. Its products include NEXTERONE, an anti arrhythmic agent in the form of injectable amiodarone; and PM103, an intravenous formulation of clopidogrel bisulfate. The company was founded in 2004 and is based in King of Prussia, Pennsylvania.

ApaTech Ltd., an ortho-biologics company, produces synthetic bone repair materials. It offers Actifuse, a synthetic bone graft, which creates a material that promotes the formation of bone and increases the volume of bone formed in the graft/host bone composite structures for small void filling and spinal fusion applications. The company also provides ApaPore, a synthetic and porous hydro-xyapatite grafting for the cemented revision of failed total joint arthroplasties for spinal fusions and fracture fixations, as well as for treating bone defects; and Actifuse MIS Bone Graft Delivery System that offers controlled delivery and precise placement for surgeons performing open and minimally invasive procedures, as well as for use in various spinal and orthopedic procedures, including posterolateral fusion, bone void filling, and acetabular cysts. It offers its products through distributors in the United Kingdom, Ireland, Norway, Sweden, Germany, Austria, Spain, Portugal, Italy, Greece, Turkey, Kuwait, Syria, Australia, and New Zealand. ApaTech Ltd. was founded in 2001 and is based in Elstree, the United Kingdom. It has operations in London, the United Kingdom; Foxborough, Massachusetts; and Berlin, Germany.

Fusion Medical Technologies manufactures proprietary surgical hemostatic sealant products. It develops collagen gel-based products for use in controlling bleeding in a variety of surgeries.

Somatogen is a biotech company developing a genetically engineered blood substitute.

Caremark provides integrated pharmacy health care services in the United States. It operates through pharmacy services and pharmacy retail. Its pharmacy services include pharmacy benefit management services, such as plan design and administration, formulary management, Medicare part D services, mail order and specialty pharmacy services, prescription management systems, clinical services, disease management, retail pharmacy network management services, discounted drug purchase arrangements, and medical spend management services. Its retail segment provides prescription drugs, over-the-counter drugs, beauty products and cosmetics, seasonal merchandise, greeting cards, and convenience foods, and other related services. It currently operates 7,705 retail drugstores, 860 health care clinics, 17 onsite pharmacies, 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies, 4 mail service dispensing pharmacies, and 84 branches, as well as 6 centers of excellence for infusion and antral services. Caremark provides its services to employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. It was established in 1892 and is headquartered in Woonsocket, Rhode Island. Caremark carries out its operations through its subsidaries.